SpyGlass Pharma financials
$25.44−2.08%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$22.0M | -$15.4M |
| Net income | -$19.9M | -$13.8M |
| Net margin | — | — |
| Diluted EPS | $-0.59 | $-0.69 |
| EBITDA | -$21.6M | -$15.1M |
| Operating cash flow | -$14.8M | -$13.5M |
| Free cash flow | -$16.8M | -$14.2M |
| Diluted shares | 33.4M | 19.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $223.1M | $238.9M |
| Short-term investments | $11.0M | $12.1M |
| Total debt | $0.00 | $0.00 |
| Total assets | $243.4M | $258.4M |
| Total liabilities | $11.1M | $8.3M |
| Shareholders' equity | $232.4M | $250.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology